Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Inclusion Criteria:

• Subject must have participated in an eligible ibrutinib clinical trial, may deriveclinical benefit from continued treatment or restart of treatment with ibrutinib inthe opinion of the treating physician and does not have access to commercialibrutinib within their region and/or the drug is not reasonably accessible to thepatient within the respective region.

• Ongoing continuous treatment with ibrutinib.

• Subject must have completed all assessments in their parent protocol and want tocontinue treatment with ibrutinib.

• Subject or their legally authorized representative must voluntarily sign and date aninformed consent approved by an independent ethics committee (IEC)/institutionalreview board (IRB) to the long term treatment extension protocol and not withdrawnconsent from the parent study.

• Male and female subjects of reproductive potential who agree to use both a highlyeffective method of birth control and a barrier method during the period of therapyand for 90 days after the last dose of drug.

Exclusion Criteria:

• Meeting any requirement in the parent protocol to permanently discontinue ibrutinibtreatment.

• Any condition or situation which, in the opinion of the treating physician, mayinterfere significantly with a subject's participation in the protocol.

• Female subjects who are pregnant, or breastfeeding, or planning to become pregnantwhile enrolled in this protocol or within 90 days of last dose of drug treatment.Male subjects who plan to father a child while enrolled in this protocol or within 90 days after the last dose of drug treatment.

• Unwilling or unable to participate in all required evaluations and procedures.

• Unable to understand the purpose and risks of the protocol and to provide a signedand dated informed consent form (ICF) and authorization to use protected healthinformation.